Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Personne :
Guillaumie, Laurence

En cours de chargement...
Photo de profil

Adresse électronique

Date de naissance

Projets de recherche

Structures organisationnelles

Fonction

Nom de famille

Guillaumie

Prénom

Laurence

Affiliation

Université Laval. Faculté des sciences infirmières

ISNI

ORCID

Identifiant Canadiana

ncf11859401

person.page.name

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • PublicationAccès libre
    The development of a community pharmacy-based intervention to optimize patients’ use of and experience with antidepressants : a step-by-step demonstration of the intervention mapping process
    (M D P I AG, 2018-05-02) Grégoire, Jean-Pierre; Guillaumie, Laurence; Gagnon, Hélène; Villeneuve, Denis; Santina, Tania; Lauzier, Sophie; Moisan, Jocelyne
    Objective: To describe the development of a community pharmacy-based intervention aimed at optimizing experience and use of antidepressants (ADs) for patients with mood and anxiety disorders. Methods: Intervention Mapping (IM) was used for conducting needs assessment, formulating intervention objectives, selecting change methods and practical applications, designing the intervention, and planning intervention implementation. IM is based on a qualitative participatory approach and each step of the intervention development process was conducted through consultations with a pharmacists’ committee. Results: A needs assessment was informed by qualitative and quantitative studies conducted with leaders, pharmacists, and patients. Intervention objectives and change methods were selected to target factors influencing patients’ experience with and use of ADs. The intervention includes four brief consultations between the pharmacist and the patient: (1) provision of information (first AD claim); (2) management of side effects (15 days after first claim); (3) monitoring treatment efficacy (30-day renewal); (4) assessment of treatment persistence (2-month renewal, repeated every 6 months). A detailed implementation plan was also developed. Conclusion: IM provided a systematic and rigorous approach to the development of an intervention directly tied to empirical data on patients’ and pharmacists’ experiences and recommendations. The thorough description of this intervention may facilitate the development of new pharmacy-based interventions or the adaptation of this intervention to other illnesses and settings.